下调和上调
生物
癌症研究
mTORC2型
黑色素瘤
塞鲁美替尼
mTORC1型
细胞生物学
PI3K/AKT/mTOR通路
MEK抑制剂
MAPK/ERK通路
激酶
遗传学
信号转导
基因
作者
Luca Ponzone,Valentina Audrito,Claudia Landi,Enrico Moiso,Chiara Levra Levron,Sara Ferrua,Aurora Savino,Nicoletta Vitale,Massimiliano Gasparrini,Lidia Avalle,Lorenza Vantaggiato,Enxhi Shaba,Beatrice Tassone,Stefania Saoncella,Francesca Orso,Daniele Viavattene,Eleonora Marina,Irene Fiorilla,Giulia Burrone,Youssef Abili
标识
DOI：10.1186/s12943-024-02010-1
摘要
The main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF-mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to assess in this context the role of mTORC2, a signaling complex defined by the presence of the essential RICTOR subunit, regarded as an oncogenic driver in several tumor types, including MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
迷人的天抒
Copyright
OK
haijun
嘻嘻哈哈
清平道人
Nole
Kao
Lian
不潮薯饼
gg
星野
jojofinter
初景
无情的聪健
skearthy
皖公网安备34019202002308
